The Absence of CD56 (NCAM) on Malignant Plasma Cells Is a Hallmark of Plasma Cell Leukemia and of a Special Subset of Multiple Myeloma

Leukemia - United Kingdom
doi 10.1038/sj.leu.2401211
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Identification of Malignant Plasma Cell Precursors in the Bone Marrow of Multiple Myeloma.

Journal of Clinical Investigation
Medicine
1985English

Anti-Myeloma Activity of MELK Inhibitor OTS167: Effects on Drug-Resistant Myeloma Cells and Putative Myeloma Stem Cell Replenishment of Malignant Plasma Cells

Blood Cancer Journal
OncologyHematology
2016English

Plasma Cell Satellitism in Plasma Cell Myeloma

Journal of Clinical Pathology
MedicineForensic MedicinePathology
2006English

Profound Impact of Sample Processing Delay on Gene Expression of Multiple Myeloma Plasma Cells

BMC Medical Genomics
Genetics
2015English

CD229 Is Expressed on the Surface of Plasma Cells Carrying an Aberrant Phenotype and Chemotherapy-Resistant Precursor Cells in Multiple Myeloma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2015English

Experimental African Trypanosome Infection Suppresses the Development of Multiple Myeloma in Mice by Inducing Intrinsic Apoptosis of Malignant Plasma Cells

Oncotarget
Oncology
2017English

Prognostic Value of CD56 Expression in Multiple Myeloma

Research in Oncology
2020English

Lymphocyte Subset Recovery and Outcome After Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma

Biology of Blood and Marrow Transplantation
TransplantationHematology
2014English

Detection of 13q Deletion in Multiple Myeloma Using Immunomagnetically Selected Plasma Cells

Revista Brasileira de Hematologia e Hemoterapia
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy